Latest Information Update: 20 Jul 1999
At a glance
- Originator AstraZeneca
- Class Antipsoriatics
- Mechanism of Action Epidermal growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 20 Jul 1999 Discontinued-I for Psoriasis in USA (Topical)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 21 Apr 1997 Phase-I clinical trials for Psoriasis in USA (Topical)